3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Glioblastoma
69
Glioma
26
Brain Neoplasms
26
Gliosarcoma
23
Melanoma
17
Central Nervous System Neoplasms
14
Astrocytoma
12
Neuroblastoma
10
Rhabdomyosarcoma
8
Small Cell Lung Carcinoma
6
Sarcoma, Ewing
6
Neoplasms
6
Neoplasm Metastasis
6
Medulloblastoma
6
Recurrence
5
Sarcoma
4
Ovarian Neoplasms
4
Osteosarcoma
4
Oligodendroglioma
4
Wilms Tumor
3
Prostatic Neoplasms
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Ependymoma
3
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Optic Nerve Glioma
2
Lymphoma, Follicular
2
Lymphoma
2
Interventions
pembrolizumab
3
fludarabine
3
Cyclophosphamide
3
Ipilimumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
sargramostim
1
reolysin
1
poly ICLC
1
peginterferon alfa-2a
1
osimertinib
1
gusacitinib
1
fludarabine phosphate
1
eprenetapopt
1
epacadostat
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vorinostat
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Poly I-C
1
Nivolumab
1
Monatide (IMS 3015)
1
Methods
1
MAPRE1 protein, human
1
Interleukin-2
1
Interleukin-15
1
Interleukin-12
1
IT-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Skin Neoplasms
×
Temozolomide
×
Clear all
NCT00715793
2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2
Completed
39 enrolled
12 charts